Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 38

References for PMC Articles for PubMed (Select 22160867)


Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties.

Pirie CM, Hackel BJ, Rosenblum MG, Wittrup KD.

J Biol Chem. 2011 Feb 11;286(6):4165-72. doi: 10.1074/jbc.M110.186973. Epub 2010 Dec 7.


Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling.

Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, Lauffenburger DA, Wittrup KD.

Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13252-7. doi: 10.1073/pnas.0913476107. Epub 2010 Jul 7.


Stability and CDR composition biases enrich binder functionality landscapes.

Hackel BJ, Ackerman ME, Howland SW, Wittrup KD.

J Mol Biol. 2010 Aug 6;401(1):84-96. doi: 10.1016/j.jmb.2010.06.004. Epub 2010 Jun 9.


Highly avid magnetic bead capture: an efficient selection method for de novo protein engineering utilizing yeast surface display.

Ackerman M, Levary D, Tobon G, Hackel B, Orcutt KD, Wittrup KD.

Biotechnol Prog. 2009 May-Jun;25(3):774-83. doi: 10.1002/btpr.174.


Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis.

Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3294-9. doi: 10.1073/pnas.0812059106. Epub 2009 Feb 13.


Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network.

Morandell S, Stasyk T, Skvortsov S, Ascher S, Huber LA.

Proteomics. 2008 Nov;8(21):4383-401. doi: 10.1002/pmic.200800204. Review.


Intracellular receptor/ligand sorting based on endosomal retention components.

French AR, Lauffenburger DA.

Biotechnol Bioeng. 1996 Aug 5;51(3):281-97.


Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling.

Hackel BJ, Kapila A, Wittrup KD.

J Mol Biol. 2008 Sep 19;381(5):1238-52. doi: 10.1016/j.jmb.2008.06.051. Epub 2008 Jun 24.


EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation.

Joslin EJ, Opresko LK, Wells A, Wiley HS, Lauffenburger DA.

J Cell Sci. 2007 Oct 15;120(Pt 20):3688-99. Epub 2007 Sep 25.


Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?

Messersmith WA, Hidalgo M.

Clin Cancer Res. 2007 Aug 15;13(16):4664-6. No abstract available.


Epidermal growth factor receptor mutations in lung cancer.

Sharma SV, Bell DW, Settleman J, Haber DA.

Nat Rev Cancer. 2007 Mar;7(3):169-81. Review.


Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.

Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, Mellinghoff IK.

PLoS Med. 2006 Dec;3(12):e485.


Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor.

Winograd-Katz SE, Levitzki A.

Oncogene. 2006 Nov 30;25(56):7381-90. Epub 2006 Jun 19. Erratum in: Oncogene. 2007 Feb 1;26(5):788.


Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK.

N Engl J Med. 2006 Feb 9;354(6):567-78.


Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast.

Kim YS, Bhandari R, Cochran JR, Kuriyan J, Wittrup KD.

Proteins. 2006 Mar 1;62(4):1026-35.


Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG.

Clin Cancer Res. 2005 Sep 1;11(17):6390-9.


Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM.

Cancer Cell. 2005 Apr;7(4):301-11.


Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy.

Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, Sela M, Yarden Y.

Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1915-20. Epub 2005 Jan 31.


Phorbol 12-myristate 13-acetate induces epidermal growth factor receptor transactivation via protein kinase Cdelta/c-Src pathways in glioblastoma cells.

Amos S, Martin PM, Polar GA, Parsons SJ, Hussaini IM.

J Biol Chem. 2005 Mar 4;280(9):7729-38. Epub 2004 Dec 23.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk